Marcus J. Glennon, Catherine I.V. Bird, Prateek Yadav, Patrick Kleine, Shayam Suseelan, Christina Boman-Markaki, Vasileia Kotoula, Matt Butler, Robert Leech, Leor Roseman, David Erritzøe, Deepak P. Srivastava, Celia Janet Ann Morgan, Christopher Timmermann, Greg Cooper, Jeremy I. Skipper, James Rucker, Sunjeev K. Kamboj, Mitul Mehta, Ravi K. Das, Anjali Bhat
Setting up a psychedelic study can be a long, arduous, and Kafkaesque process. Researchers are faced with a host of challenges in this rapidly evolving field, necessitating a range of considerations that remain largely unstandardised. Many of the complexities inherent to psychedelic research also challenge existing assumptions around, for example, approaches to psychiatric prescribing, the conceptual framing of the placebo effect, and definitions of selfhood. This review paper aims to formalise these unique considerations by addressing the sociocultural, political, legal, pharmacological, safety, study design and experiential facets inherent to a psychedelic study. We bring together several of the major psychedelic research teams across the United Kingdom, identify continuing areas of debate, and provide a practical, comprehensive, experience-based guide, with recommendations for policymakers and future researchers intending to set up a psychedelic research study or clinical trial.